IPAC2017 - List of Authors (Infantino, A.)

Paper	Title	Page
THPVA130	Modelling PET Radionuclides Production in Tissue and External Targets Using Geant4	4757
SUSPSIK117	use link to see paper's listing under its alternate paper code
	A. Amin, R.J. Barlow IIAA, Huddersfield, United Kingdom C.M. Hoehr, C. Lindsay TRIUMF, Vancouver, Canada A. Infantino CERN, Geneva, Switzerland
	The Proton Therapy Facility in TRIUMF provides 74 MeV protons extracted from a 500 MeV H⁻ cyclotron for ocular melanoma treatments. During treatment, positron emitting radionuclides such as C-11, O-15 and N-13 are produced in patient tissue. Using PET scanners, the isotopic activity distribution can be measured for in-vivo range verification. A second cyclotron, the TR13, provides 13 MeV protons onto liquid targets for the production of PET radionuclides such as F-18, N-13 or Ga-68, for medical applications. The aim of this work was to validate Geant4 against FLUKA and experimental measurements for production of the above-mentioned isotopes using the two cyclotrons. The results show variable degrees of agreement. For proton therapy, the proton-range agreement was within 2 mm for C-11 activity, whereas N-13 disagreed. For liquid targets at the TR13 the average absolute deviation ratio between FLUKA and experiment was 1.9±2.8, whereas the average absolute deviation ratio between Geant4 and experiment was 0.6±0.4. This is due to the uncertainties present in experimentally determined reaction cross sections.
DOI •	reference for this paper ※ https://doi.org/10.18429/JACoW-IPAC2017-THPVA130
Export •	reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

Paper

Title

Page

THPVA130

Modelling PET Radionuclides Production in Tissue and External Targets Using Geant4

4757

SUSPSIK117

use link to see paper's listing under its alternate paper code

A. Amin, R.J. Barlow
IIAA, Huddersfield, United Kingdom
C.M. Hoehr, C. Lindsay
TRIUMF, Vancouver, Canada
A. Infantino
CERN, Geneva, Switzerland

The Proton Therapy Facility in TRIUMF provides 74 MeV protons extracted from a 500 MeV H⁻ cyclotron for ocular melanoma treatments. During treatment, positron emitting radionuclides such as C-11, O-15 and N-13 are produced in patient tissue. Using PET scanners, the isotopic activity distribution can be measured for in-vivo range verification. A second cyclotron, the TR13, provides 13 MeV protons onto liquid targets for the production of PET radionuclides such as F-18, N-13 or Ga-68, for medical applications. The aim of this work was to validate Geant4 against FLUKA and experimental measurements for production of the above-mentioned isotopes using the two cyclotrons. The results show variable degrees of agreement. For proton therapy, the proton-range agreement was within 2 mm for C-11 activity, whereas N-13 disagreed. For liquid targets at the TR13 the average absolute deviation ratio between FLUKA and experiment was 1.9±2.8, whereas the average absolute deviation ratio between Geant4 and experiment was 0.6±0.4. This is due to the uncertainties present in experimentally determined reaction cross sections.

DOI •

reference for this paper ※ https://doi.org/10.18429/JACoW-IPAC2017-THPVA130

Export •

reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)